Mabion S.A., a Poland-based biotech, has signed a long-term development and commercialization agreement with Mylan Ireland. The agreement gives Mylan exclusive rights to sell Mabion’s biosimilar of Mabthera/Rituximab (Mabion CD20) in all EU countries and non EU Balkan states. Mylan will support Mabion in Mabion’s effort to secure approval of Mabion CD20 by the European Medicine Agency.

Mylan will pay Mabion an upfront payment of $10 million and additional milestone payments in the aggregate of up to $35 million subject to filing and approval of marketing authorizations and commercial launch in key countries, as well as royalties based on annual net sales.

“We’re excited to finalize this EU collaboration with a global player like Mylan, which has strong experience in generics and biosimilars,” said Maciej Wieczorek, chief executive officer, Mabion. “We are convinced that with our partner we will be able to ensure successful commercialization in EU after Mabion’s CD20 approval. This partnership will benefit patients in EU, Mabion and Mabion’s shareholders.”

Mabion SA is a leading biotechnology company in Poland, created for the purpose of marketing cutting-edge biotechnological drugs based on humanised monoclonal antibodies.